Total Debt for IDEXX Laboratories (IDXX)
According to IDEXX Laboratories's latest reported financial statements, the company's latest reported total debt is $1.08B USD. Total debt is the sum of short-term and long-term interest-bearing borrowings on the balance sheet (notes, bonds, term loans, lease liabilities). Useful for leverage and refinancing risk — combine with cash on hand for net debt, and see total liabilities for the broader obligations picture.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Currently viewingTotal DebtSwitch metric
Latest period
$1.08B
YoY change
+9.1%
5Y CAGR
+1.4%
Peak year (2022)
$1.47B
Latest annual
$1.08B
Total Debt history chart for IDEXX Laboratories (IDXX) from 1991 to 2025
Total Debt history table for IDEXX Laboratories (IDXX) from 1991 to 2025
| Fiscal year | Period ended | Reported | Total Debt | YoY |
|---|---|---|---|---|
| 2025 | $1.08B | +9.1% | ||
| 2024 | $986.95M | -7.5% | ||
| 2023 | $1.07B | -27.4% | ||
| 2022 | $1.47B | +42.6% | ||
| 2021 | $1.03B | +2.8% | ||
| 2020 | $1.00B | -6.3% | ||
| 2019 | $1.07B | +7.0% | ||
| 2018 | $1.00B | -20.7% | ||
| 2017 | $1.26B | +4.7% | ||
| 2016 | $1.20B | +2.9% | ||
| 2015 | $1.17B | +30.2% | ||
| 2014 | $899.00M | +109.9% | ||
| 2013 | $428.39M | +99.7% | ||
| 2012 | $214.50M | -13.0% | ||
| 2011 | $246.42M | +84.9% | ||
| 2010 | $133.28M | +7.6% | ||
| 2009 | $123.88M | -20.8% | ||
| 2008 | $156.48M | +98.9% | ||
| 2007 | $78.68M | +1004.3% | ||
| 2006 | $7.13M | +1193.1% | ||
| 2005 | $551,000 | -69.6% | ||
| 2004 | $1.81M | +41.4% | ||
| 2003 | $1.28M | +25.6% | ||
| 2002 | $1.02M | -87.8% | ||
| 2001 | $8.38M | -1.1% | ||
| 2000 | $8.47M | +120.5% | ||
| 1999 | $3.84M | -59.1% | ||
| 1998 | $9.40M | +129.3% | ||
| 1997 | $4.10M | +36.7% | ||
| 1996 | $3.00M | +76.5% | ||
| 1995 | $1.70M | — | ||
| 1994 | $0 | — | ||
| 1993 | $0 | — | ||
| 1992 | $0 | — | ||
| 1991 | $0 | — |
Total Debt values are taken from IDEXX Laboratories's reported balance sheets (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of IDEXX Laboratories (IDXX) total debt is $1.08B – grew 9.1% year-over-year.
IDEXX Laboratories total debt compound annual growth for the 2020–2025 (5 years) window is +1.4%, with the latest reading among the more recent periods of the dataset.
The highest annual total debt of $1.47B was reported in 2022. The lowest in the available history was $0 in 1991.
IDEXX Laboratories (IDXX) sits 9th of 8 Healthcare peers we track on this metric, against a peer median of $52.57B.
IDEXX Laboratories Total Debt by Year
IDEXX Laboratories Total Debt 2025: $1.08B
IDEXX Laboratories total debt in 2025 was $1.08B, grew 9.1% from 2024.
IDEXX Laboratories Total Debt 2024: $986.95M
IDEXX Laboratories total debt in 2024 was $986.95M, declined 7.5% below 2023.
IDEXX Laboratories Total Debt 2023: $1.07B
IDEXX Laboratories total debt in 2023 was $1.07B, declined 27.4% below 2022.
IDEXX Laboratories Total Debt 2022: $1.47B
IDEXX Laboratories total debt in 2022 was $1.47B, surged 42.6% from 2021. This figure represents the highest annual value in the available history.
IDEXX Laboratories Total Debt 2021: $1.03B
IDEXX Laboratories total debt in 2021 was $1.03B.
See more financial history for IDEXX Laboratories (IDXX).
Sector peers — Total Debt
Companies in the same sector as IDEXX Laboratories, ranked by their latest total debt.
| Company | Total Debt | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $130.96B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $78.39B | Healthcare |
| AbbVie Inc. (ABBV) | $69.07B | Healthcare |
| Amgen Inc. (AMGN) | $54.60B | Healthcare |
| Merck & Co., Inc. (MRK) | $50.53B | Healthcare |
| Johnson & Johnson (JNJ) | $47.93B | Healthcare |
| Eli Lilly and Company (LLY) | $42.50B | Healthcare |
| AstraZeneca PLC (AZN) | $29.70B | Healthcare |
Frequently asked questions
What is IDEXX Laboratories's total debt?
- Latest reported total debt for IDEXX Laboratories (IDXX) is $1.08B (period ending December 31, 2025).
How has IDEXX Laboratories total debt changed year-over-year?
- IDEXX Laboratories (IDXX) total debt changed +9.1% year-over-year on the latest annual filing.
What is the long-term growth rate of IDEXX Laboratories total debt?
- IDEXX Laboratories (IDXX) total debt compound annual growth rate is +1.4% over the most recent 5 years available.
When did IDEXX Laboratories total debt hit its highest annual value?
- IDEXX Laboratories total debt reached its highest annual value of $1.47B in 2022.
What was IDEXX Laboratories total debt in 2024?
- IDEXX Laboratories (IDXX) total debt in 2024 was $986.95M.
What was IDEXX Laboratories total debt in 2025?
- IDEXX Laboratories (IDXX) total debt in 2025 was $1.08B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
IDXX Overview
Company profile, financial tools, and key metrics
IDXX Revenue Counter
Earns $136.47 every second. See per minute, hour, and day.
IDXX Earnings Counter
Earns $33.60 per second net profit. See per minute, hour, and day.
IDXX Economic Scale
Exceeds Aruba's GDP. Compare with world economies.
IDXX What If Invested
What if you had invested $1,000? See historical returns from any date.
IDXX How It Makes Money
Discover visual breakdown of $4.30B in revenue — where it comes from and where it goes.
IDXX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
IDXX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
IDXX Daily Price Character
Explosive · 50.9% historical win rate (green days). Streaks & record days.
IDXX Buybacks
2.25% TTM buyback yield. Shareholder yield & SBC comparison.
IDXX Stock Split History
4 splits on record. Dates, ratios, and cumulative multiple.